How's that saying go? "You leave your job as an editor twice. Once when you stop going to work. And a second time, a bit later on, when the journal publishes the last manuscript you handled." Or something like that. Now I can rest...
English
Dave Gennert
257 posts
Dave Gennert
@DaveGennert
Scientific pubs & editing 📖, now @InSilicoMeds 💊, PhD @StanfordMed Genetics 🧬, fanatic for @RedSox ⚾️ (he/him) | tweets/opinions my own
Katılım Mart 2018
245 Takip Edilen171 Takipçiler
Leveraging #mtdna for #leukemia clonal evo & tracking-- awesome work from @livius_tacitus & Cathy Wu @DanaFarber out now in @BCD_AACR! One of those stories I was so excited to see develop as an editor, I'm happy for all authors & BCD realizing this cool tech/omics/clinical work!
Livius Penter@livius_tacitus
👋👋👋 Mitochondrial DNA mutations - how do we use them productively for understanding #clonal #evolution in #leukemia? How do they relate to somatic mutations? What about rare cells? Today, I'd like to share my recent #singlecell work in @BCD_AACR doi.org/10.1158/2643-3… /n
English
Very proud to have helped compile this @AACR Publications Collection on #disparities in cancer. So much excellent work being done to understand what drives differences in disease biology, access to care, and response to therapy. #ASCO24
Blood Cancer Discovery@BCD_AACR
Attending #ASCO24? Read the latest collection on Disparities in Cancer from the AACR Journals: bit.ly/4c0BRSj
English
Dave Gennert retweetledi
Congratulations to Owen Witte for receiving this year's @AACR Award for Outstanding Achievement in Blood Cancer Research at #AACR24! Dr. Witte sat down with us for a Q&A on his storied history in translational research, out NOW: bit.ly/4apQuOI
English
Hanging up my @BCD_AACR editor hat. THANK YOU to all authors who trusted me/us w/ your work & put faith in a new journal. Sci pub'ing may have flaws but there isn't a more dedicated team than @_TanyaBondar_ et al giving each article deserved consideration. Excited for its future!
English
Dave Gennert retweetledi
We are grateful to the entire @BCD_AACR team for developing this meeting to showcase cutting-edge preclinical and clinical findings in the fields of cancer genomics and epigenetics, precursor conditions, tumor microenvironment, immunotherapy, and precision medicine. #AACRbcd24
AACR@AACR
#AACRbcd24 cochair Riccardo Dalla-Favera closed the AACR Blood Cancer Discovery Symposium this afternoon in Boston. We thank Dr. Dalla-Favera, his cochair Kenneth Anderson, the presenters, and all of the attendees for their contributions to a great meeting. @BCD_AACR
English
Wrapping up #AACRbcd24, Ben Ebert @DanaFarber takes us through his lab's work screening for disease-associated TFs susceptible to Ub-ligase degradation. Check out his work in @BCD_AACR characterizing one such interaction, ZMYM2 degraded by avadomide+CRBN: aacrjournals.org/bloodcancerdis…
English
Dr Smith showing off @MadhavDhodapkar's work in @BCD_AACR profiling #myeloma #CARTcell patient bone marrow microenvironment to ID #singlecell correlates of response duration-- across CAR- TME, CAR+ Ts, myeloids, tumor cells: aacrjournals.org/bloodcancerdis… 3/3
#AACRbcd24 #mmsm
English
Showcasing work from @marta_chesi & @Leif_Bergsagel in @BCD_AACR on combo therapies w/ BsAb vs models of #myeloma to avoid #TcellExhaustion in hi-burden disease: aacrjournals.org/bloodcancerdis… 2/3
#AACRbcd24 #mmsm
English
A whirlwind overview of #myeloma #immunotherapy developments & targets from @ESmithMDPhD at #AACRbcd24. Highlighting work with @fdezdelarrea & @BrentjensRenier on BCMA+GPRC5D targeting to avoid antigen escape in MM @BCD_AACR: aacrjournals.org/bloodcancerdis… 1/3
English
Dr. Maus showcased her stellar work with @StefanieBailey_ in @BCD_AACR finding dispensability of IFNg in #CARTcell response > now being taken to trials: aacrjournals.org/bloodcancerdis… 2/2
#AACRbcd24 #immunotherapy
English
#CARTcell all-star @MarcelaMaus shares her latest in novel CAR targets & limiting irAEs at #AACRbcd24. Highlighting need to harmonize single-cell correlative analyses OUT NOW as InFocus in @BCD_AACR w/ @njharlen: aacrjournals.org/bloodcancerdis… 1/2
English
.@BrunoPaiva_UNAV at #AACRbcd24 on the clinical importance & promise of high-sensitivity MRD & CTC detection & kinetics in #myeloma, for risk strat, Tx guidance, resistance mech. Read his recent @BCD_AACR article demonstrating this for Ide-cel response: aacrjournals.org/bloodcancerdis…
English
Nicole Gormley (@FDAOncology) shares regulatory perspective on #hemonc trial design at #AACRbcd24: defining biomarkers, surrogate endpoints. Read her NEW perspective out now w/ @IrenemGhobrial on these considerations for #myeloma trials: aacrjournals.org/bloodcancerdis…
English
And, I mean, check out that accompanying art:
twitter.com/_TanyaBondar_/…
Tanya Bondar@_TanyaBondar_
Artwork by Tetiana Sicharenko and DeepDream AI depicts mitochondrial apoptosis priming as Charon, the ferryman who transports souls of the deceased across the River Styx to the underworld, thereby setting a threshold between life and death. @DrTonyLetai
English
🚨NEW work hot off the servers in @BCD_AACR from @DrTonyLetai & Shruti Bhatt unveiled at #AACRbcd24: #AML PDX models show lower apoptotic priming > broad resistance after acquired resistance to single Tx, & how to circumvent. doi.org/10.1158/2643-3…
#leusm #apoptosis
Dana-Farber News@DanaFarberNews
In a study published in Blood Cancer Discovery (@BCD_AACR), collaborative work from @DrTonyLetai & the Letai Lab @danafarber & Bhatt lab sheds light on the biology of relapsed cancer cells by using mouse models of acute myeloid leukemia. #AML Read more ▶️ ms.spr.ly/6019cwufZ
English
.@iannisaifantis1 presents awesome work at #AACRbcd24 discussing the regulation of T cell interactions in #myeloid maligs. Read his recent review in @BCD_AACR on the role of inflammation in myeloid disease: doi.org/10.1158/2643-3…
#leusm #AML #inflammation
English
At #AACRbcd24,@IrenemGhobrial shares experiences in early screening for #myeloma precursors-- lots more to learn in predicting prog, interaction w/ genetics & TME. Out NOW in @BCD_AACR, Irene leads discussion on MGUS/SMM clinical trials to answer those Qs: bit.ly/49KVrS4
English
Dave Gennert retweetledi
English